Keyphrases
Safety Assessment
100%
Phase 1 Clinical Trial
100%
Critical Limb Ischemia
100%
Mesenchymal Stem Cell Therapy
100%
Placenta-derived Mesenchymal Stem Cells
100%
Major Amputation
25%
Rest Pain
25%
Maximum Walking Distance
25%
Inflammatory Cytokines
12%
Blood Flow
12%
Cell-based
12%
Interleukin-1β
12%
Serum Levels
12%
Healing
12%
Phase I Clinical Trial
12%
Stem Cell Delivery
12%
T Cell Proliferation
12%
Inflammatory Conditions
12%
Human Lymphocytes
12%
Small Vessels
12%
Ankle-brachial Index
12%
Intramuscular Administration
12%
Trial Registration
12%
Tissue Loss
12%
6-month Follow-up
12%
Intramuscularly
12%
Angiography
12%
Ischemic Area
12%
Physical Performance
12%
Allogeneic Cells
12%
Group of Twenty
12%
Alleviation
12%
Mesenchymal Stem Cells
12%
Therapeutic Angiogenesis
12%
Dose-escalation Study
12%
Efficacy Outcomes
12%
Ulcer Healing
12%
Treatment-related Adverse Events
12%
Vessel Formation
12%
Minor Amputation
12%
Collateralization
12%
Lymphocyte Profile
12%
Medicine and Dentistry
Clinical Trial
100%
Safety Assessment
100%
Critical Limb Ischemia
100%
Assessment of Humans
100%
Mesenchymal Stem Cell Transplantation
100%
Mesenchymal Stem Cell
87%
Placenta
75%
Amputation
37%
Rest Pain
25%
Walking Distance
25%
Adverse Event
12%
Angiogenesis
12%
Blood Flow
12%
Serositis
12%
Interleukin 1
12%
Inflammatory Cytokine
12%
Clinical Study
12%
Ankle Brachial Index
12%
Intramuscular Injection
12%
Venous Ulcer
12%
Angiography
12%
T Cell Proliferation
12%
Physical Performance
12%
Ulcer Healing
12%
Lymphocyte
12%
Collateralization
12%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Safety Assessment
100%
Critical Limb Ischemia
100%
Adverse Event
12%
Inflammation
12%
Cytokine
12%
Clinical Study
12%
Ulcer
12%
Interleukin 1
12%
Intramuscular Injection
12%
Ulcer Healing
12%